Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a common supplement stop colon polyps? new trial aims to find out

NCT ID NCT07582003

Prevention Sponsor: Jun Gong, MD Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 05, 2026 · Updated 4 times

Summary

This early-stage trial tests whether a daily supplement called SAMe can help prevent colorectal polyps (precursors to colon cancer) in 18 adults who have already had surgery for early-stage colon cancer. Participants will take SAMe for up to a year while researchers monitor for side effects and check for new polyps during follow-up colonoscopy. The main goal is to find the safest and most effective dose for future larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 18 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Nov 2026

An estimate. Start dates often move.

Expected to finish

Nov 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults ≥18 years old with histologically confirmed, curatively resected stage I-II colorectal cancer * must agree to pre-intervention (baseline) stool sample and distal colon biopsy * must start study intervention within 30 days ±7 days of the baseline biopsy * must be able to complete up to 12 months of intervention prior to planned postoperative surveillance colonoscopy within 1 year of surgery * must undergo repeat stool sample and distal colon biopsy within 7 days ±4 days of the last dose of study intervention * did not receive adjuvant therapy * not currently breastfeeding or pregnant. Exclusion Criteria: * Have a history familial adenomatous polyposis (FAP) * have a history of hereditary nonpolyposis colorectal cancer * history of inflammatory bowel disease * high-dose aspirin (except for low-dose (≤100 mg/day) aspirin for cardiovascular prevention) within the past 60 days of enrollment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adenoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenoma colorectal cancer colorectal carcinoma colorectal neoplasm disease colorectal adenoma prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Adenoma Colorectal cancer (diagnosis)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Cedars-Sinai Medical Center

    Los Angeles, California, 90048, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.